HHCH

The following information was compiled in June 2025 and is subject to change as new research is conducted and as new information becomes available:

Description: HHCH is a semi-synthetic cannabinoid similar to other known phytocannabinoids (e.g., THC, HHC). HHCH exists as 9(R)-HHCH and 9(S)-HHCH. HHCH was first identified in September of 2023 in Sweden and reported to the European Union Drugs Agency (EUDA).¹ HHCH was identified by our laboratory in November 2024 and confirmed after acquiring standard reference material.

Sample Source: NYU Langone Health (New York City, NY)

Sample Appearance: Oral fluid (saliva)

Pharmacology: The activity and potency of HHCH have not been explicitly studied; however, due to structural similarity to other semi-synthetic cannabinoids such as HHC and HHCP, it is assumed that HHCH activates the CB₁ receptor and mimics the central nervous system effects of cannabis.^2,3

Toxicology: HHCH has been detected in one toxicology case to date at the CFSRE.

Drug Materials: HHCH has not been detected in drug materials to date at the CFSRE.

Demographics / Geographics: Toxicology specimens originated from New York, NY, and HHCH was found alongside other cannabinoids and semi-synthetic cannabinoids (e.g., THC, THCO, THCB, THCH, Carboxy-HHC), as well as ketamine.

Legal Status: HHCH is not currently a scheduled substance in the United States.

Class:

Cannabinoid

Appearance:

Oral fluid

Formula:

C22H34O2

MW:

330.5

[M+]:

330

[M+H]+:

331.2632

IUPAC:

3-hexyl-6,6,9-trimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-1-ol

Report Date:

June 19, 2025